Cyplasin Biomedical Ltd (CYPL.OB) announced that the company has been awarded a new U.S. Patent application entitled “Cytotoxic Cyplasin of the Sea Hare, Aplysia punctata, cDNA Cloning and Expression of Bioreactive Recombinants” earlier today. This patent, US 7,271,242 B2, was granted to cover the production of a cytotoxic protein by mammalian cells and the use these cells to treat cancer.
Professor Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd., commented, “This patent is an important milestone to define our intellectual property for the production method of the cytotoxic cyplasin and related proteins and its application as a substance to treat cancer. With the two US patents now in our possession, the Company will concentrate all its efforts to achieve a fast and successful development of cyplasin.”
Cyplasin Biomedical LTD is dedicated to finding new cures that kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin-SC is a protein discovered by Professor Petzelt and is derived from a common marine organism, the sea hare (Aplysia punctata).
Let us hear your thoughts: